On May 14, 2024, Kura Oncology, Inc. announced that it completed enrollment of 85 patients in the Phase 2 portion of KOMET-001, a registration-directed clinical trial of the Company's menin inhibitor, ziftomenib (KO-539), in patients with relapsed or refractory NPM1-mutant acute myeloid leukemia. The Company expects to report topline data from the trial in early 2025.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
20.82 USD | -3.48% | -4.32% | +44.78% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+44.78% | 1.59B | |
+18.15% | 124B | |
+18.02% | 112B | |
+5.07% | 22.94B | |
-12.75% | 22.22B | |
-9.86% | 17.02B | |
-14.97% | 16.88B | |
-39.94% | 16.87B | |
+2.80% | 13.63B | |
+27.39% | 11.61B |
- Stock Market
- Equities
- KURA Stock
- News Kura Oncology, Inc.
- Kura Oncology, Inc. Completes Enrollment of 85 Patients in the Phase 2 Portion of KOMET-001